GlassScriptPhysician profile
Anthony J Purcell
NPI 1548245491
$14,443.66
in general payments reported to CMS, 2019-2025
49 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,414 · 2021: $1,604 · 2022: $2,226 · 2023: $2,486 · 2024: $2,670 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,466 · Education: $23.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,465.57 |
| Education | $23.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,400.01 | 2021-2025 | |
| Novo Nordisk INC | $1,841.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,304.36 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $1,060.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,042.86 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $665.18 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $641.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.01 | 2020-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $388.91 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $372.83 | 2019-2023 | |
| Astellas Pharma US INC | $317.01 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $275.69 | 2019-2025 | |
| Corcept Therapeutics | $261.71 | 2023-2024 | Korlym |
| Amgen INC. | $242.85 | 2020-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $230.92 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.